38 results about "E6 protein" patented technology

The subject invention provides antibodies, including polyclonal and monoclonal antibodies, that bind to E6 proteins from at least three oncogenic strains of HPV. In general, the antibodies bind to amino acids motifs that are conserved between the E6 proteins of different HPV strains, particularly HPV strains 16 and 18. The subject antibodies may be used to detect HPV E6 protein in a sample, and, accordingly, the antibodies find use in a variety of diagnostic applications, including methods of diagnosing cancer. Kits for performing the subject methods and containing the subject antibodies are also provided.

The invention belongs to the technical field of biological medicine and biological detection and particularly relates to antigen epitope minimum motif peptide of a human papilloma virus (HPV) 58 type E6 protein and an application thereof. The invention provides four epitope peptides (comprising an 8-peptide sequence which can be expressed in a fusion way with carrier proteins such as truncated GST188 and the like and contain epitope minimum motif) which can be used as antigens for specifically detecting HPV 58 type virus infection in a single way or a combination way and contains the minimum motif and a marker minimum motif peptide amino acid sequence used for specifically detecting low risk type HPV virus infection and medium-high risk type HPV virus infection in a discrimination way. The amino acid sequences of the minimum motif peptides and short peptides are shown as SEQ ID No.1-SEQ ID No.9.

The invention provides a gene for encoding HPV (human papilloma virus) 6-type L2N120E7E6 fusion protein, expression vectors, a method, a bacteria strain and an application. The invention is characterized in that prokaryotic expression vectors are utilized to fuse HPV 6-type L2N-end 120 amino acids, E7 proteins and E6 proteins, and constructing the encoded gene according to the amino acid of the fusion protein. In the invention, the gene for encoding the HPV 6-type L2N120E7E6 fusion proteins is successfully designed and the expression vectors and the transformation bacteria strain of the high-expression HPV 6-type L2N120E7E6 fusion proteins are successfully constructed; and in the fusion proteins, the immunogenicity is strong, the immunoreaction of specific T cells can be induced, the tumor forming time of mice can be obviously delayed, and the growth of the tumors of 20% mice is completely restrained. The invention can be used for preventing and treating HPV 6-type infection and relevant diseases, such as genital wart.

The invention provides a human papilloma virus (HPV) 18 type L2NE7E6 fusion protein gene efficiently expressing in Escherichia coli, and an expression vector, a preparation method, a strain and a use thereof L2N protein, E7 protein and E6 protein amino acid sequences of 11th-200th amino acids of an HPV18 type L2 protein are fused, a codon optimization gene suitable for Escherichia coli expression is designed, the codon optimization gene is inserted into a prokaryotic expression vector pET9a to obtain a pET9a-HPV18L2NE7E6 expression vector and its conversion strain, the expression level accounts for 50% of all bacteria, an antibody generated by a pure fusion protein immune mouse can neutralize an HPV18 type pseudovirus in order to generate a specific T cell immune response and obviously postpone the tumor formation time of the mouse, and the growth of 20% of mouse tumors can be completely inhibited. The fusion protein can be used for developing vaccines for preventing and treating HPV18 type infection and relevant diseases.

The invention discloses an HPV58 (Human Papilloma Virus) type therapeutic composite genetic vaccine and a construction method thereof. In the vaccine, an HPV58 type E6/E7 fusion gene is used as a target antigen, and GM/B7 is used as an antigen adjuvant, wherein stop codes of HPV58 type E6 and E7 genes are removed from the HPV58 type E6/E7 fusion gene; and meanwhile, amino acids of 50, 63 and 106 on E6 protein and the amino acids 24, 26 and 92 on E7 protein are mutated into glycines. The HPV58 type therapeutic composite genetic vaccine provided by the invention has high safety, strong immunity and an ideal anti-tumor effect, provides a better choice for treating cervical carcinoma and precancerous lesion related to the HPV58 type infection, and is particularly suitable for HPV58 type highly-infective cervical carcinoma patients in China and Asia.

The present invention is directed to the examination of the pattern of immunodominant T cell epitopes in the E6 protein of Human Papilloma virus and its further characterization in terms of its amino acid sequence and Human Leukocyte Antigen restriction. These epitopes are identified based on their ability to induce specific T cell responses and therefore, are important as sources of antigens for immunotherapies to treat cervical and other cancers. The present invention contemplates identifying a number of similar epitopes restricted by a wide variety of Human Leukocyte Antigen types so that they can be used together to develop preventative or therapeutic vaccines, which can be used for the general human population. The present invention also contemplates using E6 peptides of Human Papilloma virus as a diagnosis method to predict the probability of developing persistent cervical neoplasia in an individual.

The invention discloses a medicine for treating HPV (human papillomavirus) infection and application thereof. A sequence of crRNA (crispr-derived ribonucleic acid) for targeting mRNA (messenger ribonucleic acid) for editing human papillomavirus E6 protein is shown in SEQ ID NO: 1 or SEQ ID NO:2. The designed crRNA can be used for constructing a Crispr/Cas13a system and can be used for treating theHPV infection.

The subject invention provides an antibody composition for detecting E6 protein of at least one HPV strain in a sample. The subject antibodies may be used to detect oncogenic HPV E6 proteins in a sample, and the antibodies find use in a variety of diagnostic and therapeutic applications, including methods of diagnosing and treating cancer. Kits for performing the subject methods and containing the subject antibodies are also provided. Also disclosed in the present invention is a method of generating an antibody that specifically binds to amino-terminus of E6 proteins of at least two HPV strains.

The invention relates to application of Eu-containing polyoxometalate in the in-vitro assay of the early pathogenic protein E6 of human papillomavirus, which belongs to the technical field of assaying the early pathogenic protein E6 of human papillomavirus by means of polyoxometalate. The invention utilizes the strong recognition interaction between basic amino acid-rich small peptides on EuW10 and HPV E6 proteins to assay the HPV E6 protein. A research discovers that the E6 small peptide and protein can be assembled with EuW10 into spheres to promote the remarkable enhancement of fluorescence. The invention is the first example of utilizing polyoxometalate for in-vitro E6 protein assay. The polyoxometalate EuW10 synthesis method utilized by the invention is simple and easy to obtain. The assay method disclosed by the invention has the advantages of high assay speed, simplicity and convenience in operation, simple system, stable signals and high sensitivity, and does not need any pretreatment and a complex assay instrument. Through the invention, the application of polyoxometalate as a biological probe is expanded, which is of a great significance to the pre-cancer early assay of cervical cancer.

The nucleic acid sequence provided by the invention comprises an HPV16-AVLS1 sequence and an HPV16-AVLC1 sequence in a ratio of 1: 1; the ratio of the HPV18-AVLS1 sequence to the HPV18-AVLC1 sequence is 1: 1; the sequence AVLS1 and the sequence AVLC1 respectively comprise two E6 proteins which are connected in series, two L1 short peptides, two L2 short peptides, two E7 proteins which are connected in series, a PADRE sequence and an adjuvant sequence; the N end of the sequence AVLS1 is provided with a mouse IgK secretory peptide sequence; the N end of the sequence AVLC1 is provided with a ubiquitin sequence. The nucleic acid sequence provided by the invention not only can induce a high-titer anti-E6/E7 antibody, but also can induce high-level functional cellular immunity, and shows excellent effects of preventing and treating HPV-related tumors.

The invention discloses a framework area including human HSP70 ATPase and human papillomavirus E7, E6 protein or merge protein of mammalian p53 protein. The invention also discloses a pharmaceutical compound of merge protein, gene of encoding merge protein, the expressive carrier of merge protein and the usage of preparing medicine to treat or avoid tumor as human papillomavirus or tumor related to p53 protein overdose express.

This invention relates to the minimal motif of an epitope on the E6 protein from human papilloma virus (HPV), and this minimal motif of the epitope induces a monoclonal antibody having cross-reactivity with some homologous proteins of HPVs. The inventors are the first to identify a fine antigenic epitope only existing conservatively on the E6 proteins of high risk HPV16, 33, 52 or 58). Therefore, the peptides comprising this epitope can be used to prepare immunogen or serological detection antigen against the HPV E6 proteins, or to prepare specific universal antibodies for a variety of high-risk/carcinogenic HPVs.

The invention relates to polypeptide with binding affinity to HPV16E6 protein and an application thereof, by taking a Z structural domain of a staphylococcus protein A as a bracket, randomly mutating amino acid residue simulation antibody binding sites on the surface of the Z structural domain, constructing a mutant library through a phage display technology, carrying out affinity screening on the library by taking HPV16E6 as a target antigen, and finally obtaining the polypeptide with high affinity to HPV16E6 through a large amount of screening work. Through deep research, the invention discloses the polypeptide with binding affinity to E6 protein of HPV16 for the first time, and in addition, the invention also provides diagnosis or treatment application of the polypeptide as a medicine or a molecular targeting reagent.

The invention discloses a detection method of HPV-E6 proteins. The method comprises the steps that an HPV-E6 protein reactant is prepared, an HPV-E6 protein antibody reagent is prepared, the reactant and the antibody reagent are mixed, the light absorption value of the reactant and the antibody reagent is compared with that of constant-value standard liquid, and the HPV-E6 protein content in a sample is calculated out. The method has the advantages that the sample is free of dilution, operation is easy, the accuracy is high, repeatability is good, the capacity of resisting disturbance is high, and the method is applicable to fully automatic biochemical analyzers of various types.

The invention provides reagents and methods for detecting pathogen infections in human samples. This detection utilizes specific proteins to detect the presence of pathogen proteins or abnormal expression of human proteins resulting from pathogen infections. Specific methods, compositions and kits are disclosed herein for the detection of oncogenic human papillomavirus E6 proteins in clinical samples.